{"id":"doi:10.1111/dom.14551","kind":"article","title":"Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","authors":["Sean Wharton","Salvatore Calanna","Melanie Jane Davies","Dror Dicker","Bryan Goldman","Ildiko Lingvay","Ofri Mosenzon","Domenica Rubino","Mette Thomsen","Thomas A. Wadden","Sue D. Pedersen"],"author_count":11,"year":2021,"published":"2021-09-13","venue":"Diabetes Obesity and Metabolism","cited_by":199,"doi":"10.1111/dom.14551","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1111/dom.14551","archive_url":"https://space-kitty.com/papers/doi:10.1111/dom.14551","updated":null,"pmid":"34514682","pmcid":null,"openalex_id":"W3199001556","pdf_url":null,"abstract":null,"abstract_license":null,"license":"cc-by-nc","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Pharmacology and Obesity Treatment"],"details":null,"provenance":"openalex","attribution":"Metadata and citation counts: OpenAlex (CC0).","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[]}